Medical cannabis firm Eqalis poised to close $7m funding round
Unlock all stories free for 10 days
Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
We won’t charge for 10 days. You can cancel anytime with two clicks, an email or a phone call. Find out more.
We are serious about journalism.
You will be charged in 10 days unless you cancel beforehand.
We will remind you three times before charging you.
All subscriptions auto renew but are easy to cancel.
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
Or use the information you’ve already given Google to create your subscription.
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.
Paul McBeth: Putting some PEP into the investment PIE
The Australian private equity giant is offering investors a gateway into its world.
NZ dollar at 11-week low on pending rate cuts, Biden's exit
The kiwi was trading below 60 US cents late Monday in Wellington.
The change of heart behind Arvida’s US private equity buyout
The company’s share price rose 55% after the announcement.
NZ’s “terrible” statistic
Course aims to build employee resilience & business productivity.
Digital skills shortage hurting NZ
2degrees study: many companies failing to leverage technology.
